MedTrace Logo

Efficacy and Safety of Etoricoxib+Diacerein in Osteoarthritis.

NCT07549386 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 123

Last updated 2026-04-29

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if fixed-dose combination etoricoxib 90 mg + diacerein 50 mg capsule works to treat knee/hip osteoarthritis-associated pain in adults. It will also learn about the safety of the drug. The main questions it aims to answer are:

Does etoricoxib+diacerein reduce pain intensity as per WOMAC scale after 60 days? What medical problems do participants have when taking etoricoxib 90 mg+diacerein 50 mg capsule for 60 days? Researchers will compare the test drug etoricoxib 90 mg+diacerein 50 mg capsule to an active comparator (meloxicam 15 mg + diacereina 50 mg) to see if drug ABC works to treat pain in patients with osteoarthritis.

Participants will:

Take drug the test or comparator drugs every day for 60 days. Visit the clinic once a month for health and outcomes follow-up. Keep a diary of their symptoms, pain intensity, WOMAC scale, adverse events, rescue medication use, other used drugs, and treatment adherence.

Conditions

Interventions

DRUG

Etoricoxib 90 mg + diacerein 50 mg

Once a day for 60 days

DRUG

Meloxicam 15 mg + diacerein 50 mg

Once a day for 60 days.

Sponsors & Collaborators

  • EPIC Research CRO

    collaborator INDUSTRY

  • Laboratorios Liomont

    lead INDUSTRY

Principal Investigators

  • Livan Delgado Roche, Ph.D. · Laboratorios Liomont

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-24
Primary Completion
2025-03-27
Completion
2025-10-15

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07549386 on ClinicalTrials.gov